Aurobindo Pharma, a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has received final approval for Fosinopril Sodium and Hydrocholorothizide Tablets USP 10/12.5 mg and 20/12.5 mg from the US Food and Drug Administration (USFDA).
Fosinopril Sodium and Hydrocholorothizide Tablets USP 10/12.5 mg and 20/12.5 mg is the generic equivalent to Monopril HCT(R) Tablets 10/12.5 mg and 20/12.5 mg of Bristol Myers Squibb. Fosinopril Sodium and Hydrocholorothizide Tablets are indicated for hypertension and fall under the Cario Vascular System (CVS) theraputic segment.
Content Guide
